Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 8/20 | 0.68 |
| ▸ | TLR4 | O00206 | 7/20 | 0.62 |
| ▸ | TLR2 | O60603 | 7/20 | 0.62 |
| ▸ | VCP | P55072 | 2/20 | 0.59 |
| ▸ | TERT | O14746 | 1/20 | 0.57 |
| ▸ | MAOA | P21397 | 3/20 | 0.56 |
| ▸ | MAOB | P27338 | 3/20 | 0.56 |
| ▸ | EGFR | P00533 | 1/20 | 0.53 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3235505 | 1.00 | FBP1 (0.68) | FBP1TLR4TLR2VCPTERT | |
| SCHEMBL6584626 | 0.85 | TLR4 (0.64) | FBP1TLR4TLR2VCPTERT | |
| SCHEMBL31287227 | 0.81 | FBP1 (1.00) | FBP1TLR4TLR2VCPTERT | |
| SCHEMBL278627 | 0.81 | FBP1 (1.00) | FBP1TLR4TLR2VCPTERT | |
| SCHEMBL792987 | 0.81 | FBP1 (1.00) | FBP1TLR4TLR2VCPTERT | |
| SCHEMBL8765211 | 0.81 | FBP1 (1.00) | FBP1TLR4TLR2VCPTERT | |
| SCHEMBL6041047 | 0.81 | FBP1 (0.65) | FBP1TLR4TLR2VCPEGFR | |
| SCHEMBL11525619 | 0.81 | FBP1 (0.65) | FBP1TLR4TLR2VCPEGFR | |
| SCHEMBL23343707 | 0.80 | CYP3A4 (0.56) | MAOB | |
| SCHEMBL716895 | 0.80 | KMT2A (0.60) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7745438-B2 | 3-(2-acylamino-1-hydroxyethyl)-morpholine derivatives and their use as bace inhibitors | ELI LILLY AND COMPANY (US) | 2010-06-29 | — | — | US | disclosed |
| EP-2091928-A2 | 3-(2-ACYLAMINO-1-HYDROXYETHYL)- MORPHOLINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS | ELI LILLY AND COMPANY (US) | 2009-08-26 | — | — | EP | disclosed |
| US-20070225267-A1 | 3-(2-Acylamino-1-Hydroxyethyl)-Morpholine Derivatives and Their Use as Bace Inhibitors | ELI LILLY AND COMPANY | 2007-09-27 | — | — | US | disclosed |
| WO-2006034093-A2 | 3- (2-ACYLAMINO-1-HYDROXYETHYL)- MORPHOLINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS | ELLI LILLY AND COMPANY (US) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225267-A1 | 3-(2-Acylamino-1-Hydroxyethyl)-Morpholine Derivatives and Their Use as Bace Inhibitors | BACE1, BACE2, APP | FBP1 2487/4885TLR4 4875/4885TLR2 4732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.